Cardiac Myocyte KLF5 Regulates Ppara Expression and Cardiac Function

Circulation Research

Volumn 118, Issue 2, 2016, Pages 241-253

  Drosatos, Konstantinos ^a   Pollak, Nina M ^b   Pol, Christine J ^a   Ntziachristos, Panagiotis ^c   Willecke, Florian ^d   Valenti, Mesele Christina ^a   Trent, Chad M ^d   Hu, Yunying ^d   Guo, Shaodong ^e   Aifantis, Iannis ^c   Goldberg, Ira J ^d  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF GRAZ   (Austria)

^c NEW YORK UNIVERSITY   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

cardiac myocyte; fatty acids; heart; heart failure; PPAR alpha

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; DIACYLGLYCEROL ACYLTRANSFERASE 1; KRUPPEL LIKE FACTOR 5; KRUPPEL LIKE FACTOR 6; MESSENGER RNA; PERILIPIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STRESS ACTIVATED PROTEIN KINASE; TRIACYLGLYCEROL; FATTY ACID; KLF5 PROTEIN, MOUSE; KRUPPEL LIKE FACTOR; PROTEIN BINDING; PROTEIN C JUN; SLC5A2 PROTEIN, MOUSE; SODIUM GLUCOSE COTRANSPORTER 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DIABETES MELLITUS; ENDOTHELIUM CELL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE ONTOLOGY; HEART FUNCTION; HEART MUSCLE CELL; HYPERGLYCEMIA; IN VITRO STUDY; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING COMPETITION; C57BL MOUSE; CARDIAC MUSCLE CELL; CELL LINE; DEFICIENCY; ENERGY METABOLISM; EXPERIMENTAL DIABETES MELLITUS; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHENOTYPE; TIME FACTOR; TRANSCRIPTION INITIATION;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CARDIOMYOPATHY, DILATED; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; ENERGY METABOLISM; FATTY ACIDS; GENOTYPE; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, CARDIAC; OXIDATION-REDUCTION; PHENOTYPE; PPAR ALPHA; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; SEPSIS; SIGNAL TRANSDUCTION; SODIUM-GLUCOSE TRANSPORTER 2; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TRIGLYCERIDES; UP-REGULATION;

EID: 84955268039     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.306383     Document Type: Article

References (68)

1. Stanley WC, Recchia FA, Lopaschuk GD., Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129. doi: 10.1152/physrev.00006.2004.
2. Lai L, Leone TC, Keller MP, Martin OJ, Broman AT, Nigro J, Kapoor K, Koves TR, Stevens R, Ilkayeva OR, Vega RB, Attie AD, Muoio DM, Kelly DP., Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ Heart Fail 2014;7 1022:1031. doi: 10.1161/CIRCHEARTFAILURE.114.001469.
3. Neubauer S., The failing heart-an engine out of fuel. N Engl J Med 2007-356 1140 1151. doi: 10.1056/NEJMra063052.
4. Aubert G, Vega RB, Kelly DP., Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim Biophys Acta 2013;1833:840-847. doi: 10.1016/j.bbamcr.2012.08.015.
5. Drosatos K, Drosatos-Tampakaki Z, Khan R, Homma S, Schulze PC, Zannis VI, Goldberg IJ., Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J Biol Chem 2011;286:36331-36339. doi: 10.1074/jbc.M111.272146.
6. Drosatos K, Khan RS, Trent CM, Jiang H, Son NH, Blaner WS, Homma S, Schulze PC, Goldberg IJ., Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ Heart Fail 2013;6 550:562. doi: 10.1161/CIRCHEARTFAILURE.112.000177.
7. Schilling J, Lai L, Sambandam N, Dey CE, Leone TC, Kelly DP., Toll-like receptor-mediated inflammatory signaling reprograms cardiac energy metabolism by repressing peroxisome proliferator-activated receptor γ coactivator-1 signaling. Circ Heart Fail 2011;4 474:482. doi: 10.1161/CIRCHEARTFAILURE.110.959833.
8. Madrazo JA, Kelly DP., The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol 2008-44 968 975. doi: 10.1016/j.yjmcc.2008.03.021.
9. Haemmerle G, Moustafa T, Woelkart G, ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 2011;17:1076-1085. doi: 10.1038/nm.2439.
10. Lahey R, Wang X, Carley AN, Lewandowski ED., Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride. Circulation 2014;130:1790-1799. doi: 10.1161/CIRCULATIONAHA.114.011687.
11. McConnell BB, Yang VW., Mammalian Krüppel-like factors in health and diseases. Physiol Rev 2010;90:1337-1381. doi: 10.1152/physrev.00058.2009.
12. Banerjee SS, Feinberg MW, Watanabe M, Gray S, Haspel RL, Denkinger DJ, Kawahara R, Hauner H, Jain MK., The Krüppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-gamma expression and adipogenesis. J Biol Chem 2003;278:2581-2584. doi: 10.1074/jbc.M210859200.
13. Sue N, Jack BH, Eaton SA, Pearson RC, Funnell AP, Turner J, Czolij R, Denyer G, Bao S, Molero-Navajas JC, Perkins A, Fujiwara Y, Orkin SH, Bell-Anderson K, Crossley M., Targeted disruption of the basic Krüppel-like factor gene (Klf3) reveals a role in adipogenesis. Mol Cell Biol 2008;28:3967-3978. doi: 10.1128/MCB.01942-07.
14. Kanazawa A, Kawamura Y, Sekine A, Single nucleotide polymorphisms in the gene encoding Krüppel-like factor 7 are associated with type 2 diabetes. Diabetologia 2005;48:1315-1322. doi: 10.1007/s00125-005-1797-0.
15. Birsoy K, Chen Z, Friedman J., Transcriptional regulation of adipogenesis by KLF4. Cell Metab 2008;7 339:347. doi: 10.1016/j.cmet.2008.02.001.
16. Li D, Yea S, Li S, Chen Z, Narla G, Banck M, Laborda J, Tan S, Friedman JM, Friedman SL, Walsh MJ., Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1. J Biol Chem 2005;280:26941-26952. doi: 10.1074/jbc.M500463200.
17. Mori T, Sakaue H, Iguchi H, Gomi H, Okada Y, Takashima Y, Nakamura K, Nakamura T, Yamauchi T, Kubota N, Kadowaki T, Matsuki Y, Ogawa W, Hiramatsu R, Kasuga M., Role of Krüppel-like factor 15 (KLF15) in transcriptional regulation of adipogenesis. J Biol Chem 2005;280:12867-12875. doi: 10.1074/jbc.M410515200.
18. Zhang H, Chen Q, Yang M, Zhu B, Cui Y, Xue Y, Gong N, Cui A, Wang M, Shen L, Zhang S, Fang F, Chang Y., Mouse KLF11 regulates hepatic lipid metabolism. J Hepatol 2013;58:763-770. doi: 10.1016/j.jhep.2012.11.024.
19. Prosdocimo DA, Anand P, Liao X, Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism. J Biol Chem 2014;289:5914-5924. doi: 10.1074/jbc.M113.531384.
20. Haldar SM, Jeyaraj D, Anand P, Kruppel-like factor 15 regulates skeletal muscle lipid flux and exercise adaptation. Proc Natl Acad Sci USA 2012;109:6739-6744. doi: 10.1073/pnas.1121060109.
21. Shindo T, Manabe I, Fukushima Y, Krüppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat Med 2002;8 856:863. doi: 10.1038/nm738.
22. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, Nishimura S, Shindo T, Sano M, Otsu K, Snider P, Conway SJ, Nagai R., Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 2010-120 254 265. doi: 10.1172/JCI40295.
23. Oishi Y, Manabe I, Tobe K, Ohsugi M, Kubota T, Fujiu K, Maemura K, Kubota N, Kadowaki T, Nagai R., SUMOylation of Krüppel-like transcription factor 5 acts as a molecular switch in transcriptional programs of lipid metabolism involving PPAR-delta. Nat Med 2008;14:656-666. doi: 10.1038/nm1756.
24. Wan H, Luo F, Wert SE, Zhang L, Xu Y, Ikegami M, Maeda Y, Bell SM, Whitsett JA., Kruppel-like factor 5 is required for perinatal lung morphogenesis and function. Development 2008;135:2563-2572. doi: 10.1242/dev.021964.
25. Claycomb WC, Lanson NA Jr, Stallworth BS, Egeland DB, Delcarpio JB, Bahinski A, Izzo NJ Jr., HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998;95:2979-2984
26. Liao X, Haldar SM, Lu Y, Jeyaraj D, Paruchuri K, Nahori M, Cui Y, Kaestner KH, Jain MK., Krüppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J Mol Cell Cardiol 2010;49:334-338. doi: 10.1016/j.yjmcc.2010.04.008.
27. Musti AM, Treier M, Bohmann D., Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997;275:400-402
28. Guo S., Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol 2014;220:T1-T23. doi: 10.1530/JOE-13-0327.
29. Keeton AB, Amsler MO, Venable DY, Messina JL., Insulin signal transduction pathways and insulin-induced gene expression. J Biol Chem 2002;277:48565-48573. doi: 10.1074/jbc.M207837200.
30. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ, Cooksey RC, Litwin SE, Abel ED., Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-5349. doi: 10.1210/en.2005-0938.
31. Rame JE, Barouch LA, Sack MN, Caloric restriction in leptin deficiency does not correct myocardial steatosis: failure to normalize PPAR{alpha}/PGC1{alpha} and thermogenic glycerolipid/fatty acid cycling. Physiol Genomics 2011;43:726-738. doi: 10.1152/physiolgenomics.00088.2010.
32. Tönjes A, Kovacs P., SGLT2: a potential target for the pharmacogenetics of type 2 diabetes? Pharmacogenomics 2013;14:825-833. doi: 10.2217/pgs.13.61.
33. Bugger H, Chen D, Riehle C, Soto J, Theobald HA, Hu XX, Ganesan B, Weimer BC, Abel ED., Tissue-specific remodeling of the mitochondrial proteome in type 1 diabetic akita mice. Diabetes 2009;58:1986-1997. doi: 10.2337/db09-0259.
34. Bugger H, Riehle C, Jaishy B, Genetic loss of insulin receptors worsens cardiac efficiency in diabetes. J Mol Cell Cardiol 2012;52:1019-1026. doi: 10.1016/j.yjmcc.2012.02.001.
35. Kewalramani G, An D, Kim MS, Ghosh S, Qi D, Abrahani A, Pulinilkunnil T, Sharma V, Wambolt RB, Allard MF, Innis SM, Rodrigues B., AMPK control of myocardial fatty acid metabolism fluctuates with the intensity of insulin-deficient diabetes. J Mol Cell Cardiol 2007;42:333-342. doi: 10.1016/j.yjmcc.2006.11.010.
36. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP., The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 2002;109:121-130. doi: 10.1172/JCI14080.
37. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C, Gropler RJ., Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006;47:598-604. doi: 10.1016/j.jacc.2005.09.030.
38. Duncan JG, Finck BN., The PPARalpha-PGC-1alpha axis controls cardiac energy metabolism in healthy and diseased myocardium. PPAR Res 2008;2008:253817. doi: 10.1155/2008/253817.
39. Chokshi A, Drosatos K, Cheema FH, Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012-125 2844 2853. doi: 10.1161/CIRCULATIONAHA.111.060889.
40. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC., Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207-258. doi: 10.1152/physrev.00015.2009.
41. Oishi Y, Manabe I, Tobe K, Tsushima K, Shindo T, Fujiu K, Nishimura G, Maemura K, Yamauchi T, Kubota N, Suzuki R, Kitamura T, Akira S, Kadowaki T, Nagai R., Krüppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metab 2005;1 27:39. doi: 10.1016/j.cmet.2004.11.005.
42. Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M., Cardiac hypertrophy is enhanced in PPAR alpha-/-mice in response to chronic pressure overload. Cardiovasc Res 2008-78 79 89. doi: 10.1093/cvr/cvn001.
43. Chanchevalap S, Nandan MO, McConnell BB, Charrier L, Merlin D, Katz JP, Yang VW., Kruppel-like factor 5 is an important mediator for lipopolysaccharide-induced proinflammatory response in intestinal epithelial cells. Nucleic Acids Res 2006;34:1216-1223. doi: 10.1093/nar/gkl014.
44. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramírez E, Egido J, Tunõn J., Potential role of nuclear factor κB in diabetic cardiomyopathy. Mediators Inflamm 2011;2011:652097. doi: 10.1155/2011/652097.
45. Palomer X, Salvadó L, Barroso E, Vázquez-Carrera M., An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol 2013-168 3160 3172. doi: 10.1016/j.ijcard.2013.07.150.
46. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ., Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008;49:2101-2112. doi: 10.1194/jlr.M800147-JLR200.
47. Tomita T, Wilson L, Chiga M., Idiopathic dilated cardiomyopathy-an evidence of abnormal lipid accumulation accumulation in myocardium. Am J Cardiovasc Pathol 1990;3 81:85
48. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H., Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004-18 1692 1700. doi: 10.1096/fj.04-2263com.
49. Drosatos K, Bharadwaj KG, Lymperopoulos A, Ikeda S, Khan R, Hu Y, Agarwal R, Yu S, Jiang H, Steinberg SF, Blaner WS, Koch WJ, Goldberg IJ., Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab 2011;300:E489-E499. doi: 10.1152/ajpendo.00569.2010.
50. Iemitsu M, Miyauchi T, Maeda S, Tanabe T, Takanashi M, Irukayama-Tomobe Y, Sakai S, Ohmori H, Matsuda M, Yamaguchi I., Aging-induced decrease in the PPAR-alpha level in hearts is improved by exercise training. Am J Physiol Heart Circ Physiol 2002;283:H1750-H1760. doi: 10.1152/ajpheart.01051.2001.
51. Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R., Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009;119:2818-2828. doi: 10.1161/CIRCULATIONAHA.108.832915.
52. Djouadi F, Weinheimer CJ, Saffitz JE, Pitchford C, Bastin J, Gonzalez FJ, Kelly DP., A gender-related defect in lipid metabolism and glucose homeostasis in peroxisome proliferator-activated receptor alpha-deficient mice. J Clin Invest 1998;102:1083-1091. doi: 10.1172/JCI3949.
53. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y, Gonzalez FJ, Aoyama T., Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity. J Biol Chem 2000;275:22293-22299. doi: 10.1074/jbc.M000248200.
54. Howroyd P, Swanson C, Dunn C, Cattley RC, Corton JC., Decreased longevity and enhancement of age-dependent lesions in mice lacking the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha). Toxicol Pathol 2004;32:591-599
55. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, Severson DL, Kelly DP, Lopaschuk GD., A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 2002;277:4098-4103. doi: 10.1074/jbc.M106054200.
56. Guellich A, Damy T, Lecarpentier Y, Conti M, Claes V, Samuel JL, Quillard J, Hébert JL, Pineau T, Coirault C., Role of oxidative stress in cardiac dysfunction of PPARalpha-/-mice. Am J Physiol Heart Circ Physiol 2007;293:H93-H102. doi: 10.1152/ajpheart.00037.2007.
57. Duhaney TA, Cui L, Rude MK, Lebrasseur NK, Ngoy S, De Silva DS, Siwik DA, Liao R, Sam F., Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 2007;49:1084-1094. doi: 10.1161/HYPERTENSIONAHA.107.086926.
58. Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P., Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4. Mol Cell Endocrinol 2013;370:103-112. doi: 10.1016/j.mce.2013.03.006.
59. Oka S, Alcendor R, Zhai P, Park JY, Shao D, Cho J, Yamamoto T, Tian B, Sadoshima J., PPARα-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab 2011;14:598-611. doi: 10.1016/j.cmet.2011.10.001.
60. Folmes CD, Sowah D, Clanachan AS, Lopaschuk GD., High rates of residual fatty acid oxidation during mild ischemia decrease cardiac work and efficiency. J Mol Cell Cardiol 2009;47:142-148. doi: 10.1016/j.yjmcc.2009.03.005.
61. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, Tserng KY, Hoit BD, Stanley WC, Chandler MP., Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 2006;290:H1899-H1904. doi: 10.1152/ajpheart.01014.2005.
62. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD., Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol 2006;290:H87-H95. doi: 10.1152/ajpheart.00285.2005.
63. Duerr GD, Heinemann JC, Arnoldi V, Feisst A, Kley J, Ghanem A, Welz A, Dewald O., Cardiomyocyte specific peroxisome proliferator-activated receptor-α overexpression leads to irreversible damage in ischemic murine heart. Life Sci 2014;102:88-97. doi: 10.1016/j.lfs.2014.03.019.
64. Ravingerová T, Carnická S, Ledvényiová V, Barlaka E, Galatou E, Chytilová A, Mandíková P, Nemčeková M, Adameová A, Kolář F, Lazou A., Upregulation of genes involved in cardiac metabolism enhances myocardial resistance to ischemia/reperfusion in the rat heart. Physiol Res 2013;62:suppl 1-S151 S163
65. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C., Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002;16:1027-1040. doi: 10.1096/fj.01-0793com.
66. Huang JP, Huang SS, Deng JY, Hung LM., Impairment of insulin-stimulated Akt/GLUT4 signaling is associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats. J Biomed Sci 2009;16:77. doi: 10.1186/1423-0127-16-77.
67. Banke NH, Lewandowski ED., Impaired cytosolic NADH shuttling and elevated UCP3 contribute to inefficient citric acid cycle flux support of postischemic cardiac work in diabetic hearts. J Mol Cell Cardiol 2015;79:13-20. doi: 10.1016/j.yjmcc.2014.10.015.
68. Young ME, Patil S, Ying J, Depre C, Ahuja HS, Shipley GL, Stepkowski SM, Davies PJ, Taegtmeyer H., Uncoupling protein 3 transcription is regulated by peroxisome proliferator-activated receptor (alpha) in the adult rodent heart. FASEB J 2001;15:833-845. doi: 10.1096/fj.00-0351com.